Cargando…

Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation

Patients with late‐stage Kellgren‐Lawrence knee osteoarthritis received a single intra‐articular injection of 1, 10, or 50 million bone marrow mesenchymal stromal cells (BM‐MSCs) in a phase I/IIa trial to assess safety and efficacy using a broad toolset of analytical methods. Besides safety, outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Chahal, Jaskarndip, Gómez‐Aristizábal, Alejandro, Shestopaloff, Konstantin, Bhatt, Shashank, Chaboureau, Amélie, Fazio, Antonietta, Chisholm, Jolene, Weston, Amanda, Chiovitti, Julia, Keating, Armand, Kapoor, Mohit, Ogilvie‐Harris, Darrell J., Syed, Khalid A., Gandhi, Rajiv, Mahomed, Nizar N., Marshall, Kenneth W., Sussman, Marshall S., Naraghi, Ali M., Viswanathan, Sowmya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646697/
https://www.ncbi.nlm.nih.gov/pubmed/30964245
http://dx.doi.org/10.1002/sctm.18-0183
_version_ 1783437593893928960
author Chahal, Jaskarndip
Gómez‐Aristizábal, Alejandro
Shestopaloff, Konstantin
Bhatt, Shashank
Chaboureau, Amélie
Fazio, Antonietta
Chisholm, Jolene
Weston, Amanda
Chiovitti, Julia
Keating, Armand
Kapoor, Mohit
Ogilvie‐Harris, Darrell J.
Syed, Khalid A.
Gandhi, Rajiv
Mahomed, Nizar N.
Marshall, Kenneth W.
Sussman, Marshall S.
Naraghi, Ali M.
Viswanathan, Sowmya
author_facet Chahal, Jaskarndip
Gómez‐Aristizábal, Alejandro
Shestopaloff, Konstantin
Bhatt, Shashank
Chaboureau, Amélie
Fazio, Antonietta
Chisholm, Jolene
Weston, Amanda
Chiovitti, Julia
Keating, Armand
Kapoor, Mohit
Ogilvie‐Harris, Darrell J.
Syed, Khalid A.
Gandhi, Rajiv
Mahomed, Nizar N.
Marshall, Kenneth W.
Sussman, Marshall S.
Naraghi, Ali M.
Viswanathan, Sowmya
author_sort Chahal, Jaskarndip
collection PubMed
description Patients with late‐stage Kellgren‐Lawrence knee osteoarthritis received a single intra‐articular injection of 1, 10, or 50 million bone marrow mesenchymal stromal cells (BM‐MSCs) in a phase I/IIa trial to assess safety and efficacy using a broad toolset of analytical methods. Besides safety, outcomes included patient‐reported outcome measures (PROMs): Knee Injury and Osteoarthritis Outcome Score (KOOS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); contrast‐enhanced magnetic resonance imaging (MRI) for cartilage morphology (Whole Organ MRI Scores [WORMS]), collagen content (T2 scores), and synovitis; and inflammation and cartilage turnover biomarkers, all over 12 months. BM‐MSCs were characterized by a panel of anti‐inflammatory markers to predict clinical efficacy. There were no serious adverse events, although four patients had minor, transient adverse events. There were significant overall improvements in KOOS pain, symptoms, quality of life, and WOMAC stiffness relative to baseline; the 50 million dose achieved clinically relevant improvements across most PROMs. WORMS and T2 scores did not change relative to baseline. However, cartilage catabolic biomarkers and MRI synovitis were significantly lower at higher doses. Pro‐inflammatory monocytes/macrophages and interleukin 12 levels decreased in the synovial fluid after MSC injection. The panel of BM‐MSC anti‐inflammatory markers was strongly predictive of PROMs over 12 months. Autologous BM‐MSCs are safe and result in significant improvements in PROMs at 12 months. Our analytical tools provide important insights into BM‐MSC dosing and BM‐MSC reduction of synovial inflammation and cartilage degradation and provide a highly predictive donor selection criterion that will be critical in translating MSC therapy for osteoarthritis. stem cells translational medicine 2019;8:746&757
format Online
Article
Text
id pubmed-6646697
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-66466972019-07-31 Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation Chahal, Jaskarndip Gómez‐Aristizábal, Alejandro Shestopaloff, Konstantin Bhatt, Shashank Chaboureau, Amélie Fazio, Antonietta Chisholm, Jolene Weston, Amanda Chiovitti, Julia Keating, Armand Kapoor, Mohit Ogilvie‐Harris, Darrell J. Syed, Khalid A. Gandhi, Rajiv Mahomed, Nizar N. Marshall, Kenneth W. Sussman, Marshall S. Naraghi, Ali M. Viswanathan, Sowmya Stem Cells Transl Med Human Clinical Article Patients with late‐stage Kellgren‐Lawrence knee osteoarthritis received a single intra‐articular injection of 1, 10, or 50 million bone marrow mesenchymal stromal cells (BM‐MSCs) in a phase I/IIa trial to assess safety and efficacy using a broad toolset of analytical methods. Besides safety, outcomes included patient‐reported outcome measures (PROMs): Knee Injury and Osteoarthritis Outcome Score (KOOS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); contrast‐enhanced magnetic resonance imaging (MRI) for cartilage morphology (Whole Organ MRI Scores [WORMS]), collagen content (T2 scores), and synovitis; and inflammation and cartilage turnover biomarkers, all over 12 months. BM‐MSCs were characterized by a panel of anti‐inflammatory markers to predict clinical efficacy. There were no serious adverse events, although four patients had minor, transient adverse events. There were significant overall improvements in KOOS pain, symptoms, quality of life, and WOMAC stiffness relative to baseline; the 50 million dose achieved clinically relevant improvements across most PROMs. WORMS and T2 scores did not change relative to baseline. However, cartilage catabolic biomarkers and MRI synovitis were significantly lower at higher doses. Pro‐inflammatory monocytes/macrophages and interleukin 12 levels decreased in the synovial fluid after MSC injection. The panel of BM‐MSC anti‐inflammatory markers was strongly predictive of PROMs over 12 months. Autologous BM‐MSCs are safe and result in significant improvements in PROMs at 12 months. Our analytical tools provide important insights into BM‐MSC dosing and BM‐MSC reduction of synovial inflammation and cartilage degradation and provide a highly predictive donor selection criterion that will be critical in translating MSC therapy for osteoarthritis. stem cells translational medicine 2019;8:746&757 John Wiley & Sons, Inc. 2019-04-09 /pmc/articles/PMC6646697/ /pubmed/30964245 http://dx.doi.org/10.1002/sctm.18-0183 Text en © 2019 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Human Clinical Article
Chahal, Jaskarndip
Gómez‐Aristizábal, Alejandro
Shestopaloff, Konstantin
Bhatt, Shashank
Chaboureau, Amélie
Fazio, Antonietta
Chisholm, Jolene
Weston, Amanda
Chiovitti, Julia
Keating, Armand
Kapoor, Mohit
Ogilvie‐Harris, Darrell J.
Syed, Khalid A.
Gandhi, Rajiv
Mahomed, Nizar N.
Marshall, Kenneth W.
Sussman, Marshall S.
Naraghi, Ali M.
Viswanathan, Sowmya
Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation
title Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation
title_full Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation
title_fullStr Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation
title_full_unstemmed Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation
title_short Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation
title_sort bone marrow mesenchymal stromal cell treatment in patients with osteoarthritis results in overall improvement in pain and symptoms and reduces synovial inflammation
topic Human Clinical Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646697/
https://www.ncbi.nlm.nih.gov/pubmed/30964245
http://dx.doi.org/10.1002/sctm.18-0183
work_keys_str_mv AT chahaljaskarndip bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT gomezaristizabalalejandro bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT shestopaloffkonstantin bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT bhattshashank bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT chaboureauamelie bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT fazioantonietta bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT chisholmjolene bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT westonamanda bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT chiovittijulia bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT keatingarmand bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT kapoormohit bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT ogilvieharrisdarrellj bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT syedkhalida bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT gandhirajiv bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT mahomednizarn bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT marshallkennethw bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT sussmanmarshalls bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT naraghialim bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation
AT viswanathansowmya bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation